Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1996 Sep 15;98(6):1441–1448. doi: 10.1172/JCI118932

Endogenous interleukin 6 production in multiple myeloma patients treated with chimeric monoclonal anti-IL6 antibodies indicates the existence of a positive feed-back loop.

H C van Zaanen 1, R P Koopmans 1, L A Aarden 1, H J Rensink 1, J M Stouthard 1, S O Warnaar 1, H M Lokhorst 1, M H van Oers 1
PMCID: PMC507571  PMID: 8823310

Abstract

In vitro as well as in vivo observations have shown that IL6 plays a key role in the pathogenesis of multiple myeloma. Therefore we started a phase I/II dose escalating study with chimeric monoclonal anti-IL6 antibodies (cMab) in multiple myeloma (MM) patients resistant to second-line chemotherapy. Here we describe the pharmacological data as well as a new method for calculating the endogenous IL6 production. The cMab (CLB IL6/8; Kd: 6.25 x 10(-12) M) was given in two cycles of 14 daily infusions, starting on day 1 and day 28. Daily dose: 5 mg in patients 1-3, 10 mg in patients 4-6, and 20 mg in patients 7-9 (total dose 140, 280, and 560 mg of anti-IL6, respectively). Using the pharmacokinetic data of free IL6 and the binding characteristics of the cMab, the endogenous IL6 production could be calculated from day to day using a one-compartment open model. The median half-life time of this antibody was 17.6 d. No human antichimeric antibodies were induced. Pre-treatment median endogenous IL6 production in the MM patients was 60 micrograms/d (range 13.8-230; normal controls < 7 micrograms/d). During treatment with anti-IL6 cMabs, the endogenous IL6 production immediately decreased in all patients to below 3 micrograms/d and never reached the pre-treatment value during the treatment period, except in two patients who developed an active infection, resulting in an IL6 production of 128 and 1,208 micrograms/d, respectively. We concluded that in MM patients endogenous IL6 production is 2-30 times higher than in healthy individuals. The anti-IL6 cMab strongly suppress this endogenous IL6 production, probably by blocking a positive feed-back loop, but this cMab does not prevent infection-induced IL6 production. The chimeric anti-IL6 Mabs have a long half-life time, a low immunogenicity, and are able to block IL6-dependent processes in vivo.

Full Text

The Full Text of this article is available as a PDF (189.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aarden L. A., De Groot E. R., Schaap O. L., Lansdorp P. M. Production of hybridoma growth factor by human monocytes. Eur J Immunol. 1987 Oct;17(10):1411–1416. doi: 10.1002/eji.1830171004. [DOI] [PubMed] [Google Scholar]
  2. Anderson K. C., Jones R. M., Morimoto C., Leavitt P., Barut B. A. Response patterns of purified myeloma cells to hematopoietic growth factors. Blood. 1989 May 15;73(7):1915–1924. [PubMed] [Google Scholar]
  3. Bataille R., Barlogie B., Lu Z. Y., Rossi J. F., Lavabre-Bertrand T., Beck T., Wijdenes J., Brochier J., Klein B. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma. Blood. 1995 Jul 15;86(2):685–691. [PubMed] [Google Scholar]
  4. Bataille R., Jourdan M., Zhang X. G., Klein B. Serum levels of interleukin 6, a potent myeloma cell growth factor, as a reflect of disease severity in plasma cell dyscrasias. J Clin Invest. 1989 Dec;84(6):2008–2011. doi: 10.1172/JCI114392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Brakenhoff J. P., Hart M., De Groot E. R., Di Padova F., Aarden L. A. Structure-function analysis of human IL-6. Epitope mapping of neutralizing monoclonal antibodies with amino- and carboxyl-terminal deletion mutants. J Immunol. 1990 Jul 15;145(2):561–568. [PubMed] [Google Scholar]
  6. Castell J. V., Geiger T., Gross V., Andus T., Walter E., Hirano T., Kishimoto T., Heinrich P. C. Plasma clearance, organ distribution and target cells of interleukin-6/hepatocyte-stimulating factor in the rat. Eur J Biochem. 1988 Nov 1;177(2):357–361. doi: 10.1111/j.1432-1033.1988.tb14384.x. [DOI] [PubMed] [Google Scholar]
  7. Castell J., Klapproth J., Gross V., Walter E., Andus T., Snyers L., Content J., Heinrich P. C. Fate of interleukin-6 in the rat. Involvement of skin in its catabolism. Eur J Biochem. 1990 Apr 20;189(1):113–118. doi: 10.1111/j.1432-1033.1990.tb15466.x. [DOI] [PubMed] [Google Scholar]
  8. Durie B. G., Salmon S. E. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975 Sep;36(3):842–854. doi: 10.1002/1097-0142(197509)36:3<842::aid-cncr2820360303>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  9. Ehlers M., Grötzinger J., deHon F. D., Müllberg J., Brakenhoff J. P., Liu J., Wollmer A., Rose-John S. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J Immunol. 1994 Aug 15;153(4):1744–1753. [PubMed] [Google Scholar]
  10. Heinrich P. C., Castell J. V., Andus T. Interleukin-6 and the acute phase response. Biochem J. 1990 Feb 1;265(3):621–636. doi: 10.1042/bj2650621. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Helle M., Boeije L., de Groot E., de Vos A., Aarden L. Sensitive ELISA for interleukin-6. Detection of IL-6 in biological fluids: synovial fluids and sera. J Immunol Methods. 1991 Apr 8;138(1):47–56. doi: 10.1016/0022-1759(91)90063-l. [DOI] [PubMed] [Google Scholar]
  12. Heremans H., Dillen C., Put W., Van Damme J., Billiau A. Protective effect of anti-interleukin (IL)-6 antibody against endotoxin, associated with paradoxically increased IL-6 levels. Eur J Immunol. 1992 Sep;22(9):2395–2401. doi: 10.1002/eji.1830220932. [DOI] [PubMed] [Google Scholar]
  13. Hoffman T. Anticipating, recognizing, and preventing hazards associated with in vivo use of monoclonal antibodies: special considerations related to human anti-mouse antibodies. Cancer Res. 1990 Feb 1;50(3 Suppl):1049s–1050s. [PubMed] [Google Scholar]
  14. Kawano M., Hirano T., Matsuda T., Taga T., Horii Y., Iwato K., Asaoku H., Tang B., Tanabe O., Tanaka H. Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas. Nature. 1988 Mar 3;332(6159):83–85. doi: 10.1038/332083a0. [DOI] [PubMed] [Google Scholar]
  15. Klein B., Brailly H. Cytokine-binding proteins: stimulating antagonists. Immunol Today. 1995 May;16(5):216–220. doi: 10.1016/0167-5699(95)80161-8. [DOI] [PubMed] [Google Scholar]
  16. Klein B., Wijdenes J., Zhang X. G., Jourdan M., Boiron J. M., Brochier J., Liautard J., Merlin M., Clement C., Morel-Fournier B. Murine anti-interleukin-6 monoclonal antibody therapy for a patient with plasma cell leukemia. Blood. 1991 Sep 1;78(5):1198–1204. [PubMed] [Google Scholar]
  17. Klein B., Zhang X. G., Jourdan M., Boiron J. M., Portier M., Lu Z. Y., Wijdenes J., Brochier J., Bataille R. Interleukin-6 is the central tumor growth factor in vitro and in vivo in multiple myeloma. Eur Cytokine Netw. 1990 Oct-Nov;1(4):193–201. [PubMed] [Google Scholar]
  18. Klein B., Zhang X. G., Jourdan M., Content J., Houssiau F., Aarden L., Piechaczyk M., Bataille R. Paracrine rather than autocrine regulation of myeloma-cell growth and differentiation by interleukin-6. Blood. 1989 Feb;73(2):517–526. [PubMed] [Google Scholar]
  19. Lokhorst H. M., Lamme T., de Smet M., Klein S., de Weger R. A., van Oers R., Bloem A. C. Primary tumor cells of myeloma patients induce interleukin-6 secretion in long-term bone marrow cultures. Blood. 1994 Oct 1;84(7):2269–2277. [PubMed] [Google Scholar]
  20. Lu Z. Y., Brailly H., Wijdenes J., Bataille R., Rossi J. F., Klein B. Measurement of whole body interleukin-6 (IL-6) production: prediction of the efficacy of anti-IL-6 treatments. Blood. 1995 Oct 15;86(8):3123–3131. [PubMed] [Google Scholar]
  21. Lu Z. Y., Brochier J., Wijdenes J., Brailly H., Bataille R., Klein B. High amounts of circulating interleukin (IL)-6 in the form of monomeric immune complexes during anti-IL-6 therapy. Towards a new methodology for measuring overall cytokine production in human in vivo. Eur J Immunol. 1992 Nov;22(11):2819–2824. doi: 10.1002/eji.1830221110. [DOI] [PubMed] [Google Scholar]
  22. Martens E., Dillen C., Put W., Heremans H., van Damme J., Billiau A. Increased circulating interleukin-6 (IL-6) activity in endotoxin-challenged mice pretreated with anti-IL-6 antibody is due to IL-6 accumulated in antigen-antibody complexes. Eur J Immunol. 1993 Aug;23(8):2026–2029. doi: 10.1002/eji.1830230846. [DOI] [PubMed] [Google Scholar]
  23. May L. T., Neta R., Moldawer L. L., Kenney J. S., Patel K., Sehgal P. B. Antibodies chaperone circulating IL-6. Paradoxical effects of anti-IL-6 "neutralizing" antibodies in vivo. J Immunol. 1993 Sep 15;151(6):3225–3236. [PubMed] [Google Scholar]
  24. May L. T., Patel K., García D., Ndubuisi M. I., Ferrone S., Mittelman A., Mackiewicz A., Sehgal P. B. Sustained high levels of circulating chaperoned interleukin-6 after active specific cancer immunotherapy. Blood. 1994 Sep 15;84(6):1887–1895. [PubMed] [Google Scholar]
  25. Mihara M., Koishihara Y., Fukui H., Yasukawa K., Ohsugi Y. Murine anti-human IL-6 monoclonal antibody prolongs the half-life in circulating blood and thus prolongs the bioactivity of human IL-6 in mice. Immunology. 1991 Sep;74(1):55–59. [PMC free article] [PubMed] [Google Scholar]
  26. Nordan R. P., Pumphrey J. G., Rudikoff S. Purification and NH2-terminal sequence of a plasmacytoma growth factor derived from the murine macrophage cell line P388D1. J Immunol. 1987 Aug 1;139(3):813–817. [PubMed] [Google Scholar]
  27. Tienhaara A., Pulkki K., Mattila K., Irjala K., Pelliniemi T. T. Serum immunoreactive interleukin-6 and C-reactive protein levels in patients with multiple myeloma at diagnosis. Br J Haematol. 1994 Feb;86(2):391–393. doi: 10.1111/j.1365-2141.1994.tb04748.x. [DOI] [PubMed] [Google Scholar]
  28. Zhang X. G., Klein B., Bataille R. Interleukin-6 is a potent myeloma-cell growth factor in patients with aggressive multiple myeloma. Blood. 1989 Jul;74(1):11–13. [PubMed] [Google Scholar]
  29. van Oers M. H., van Zaanen H. C., Lokhorst H. M. Interleukin-6, a new target for therapy in multiple myeloma? Ann Hematol. 1993 May;66(5):219–223. doi: 10.1007/BF01738469. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES